category,datetime,headline,id,image,related,source,summary,url
company,1768489200,Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer,138121855,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,HSIC,Yahoo,"IRVINE, Calif., January 15, 2026--Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care",https://finnhub.io/api/news?id=0f9647da3f0e914d46151f8d465bd73a62fc3e099a5b363fd2a567669995ef7e
company,1768449980,3 Reasons to Sell HSIC and 1 Stock to Buy Instead,138121856,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,HSIC,Yahoo,"Henry Schein trades at $76.27 per share and has stayed right on track with the overall market, gaining 8% over the last six months. At the same time, the S&P 500 has returned 11.5%.",https://finnhub.io/api/news?id=d06087c7bf3b0ca3ca2ce4cd2759f3540190dfd744fc63d686920d05baae7759
